The Mystical Experience as Medicine: What the Trials Are Measuring

“The MEQ30 measures six features: unity, noetic quality, sacredness, deeply felt positive mood, transcendence of time and space, and ineffability. These are Huxley's criteria, operationalized seventy years later.”

Aldous Huxley called the mescaline experience a 'gratuitous grace', not necessary to salvation but potentially helpful, to be accepted thankfully if made available. He located it within the category of mystical experience as defined by the philosophical and theological literature: a direct encounter with what he called 'the divine Ground,' characterized by unity, noetic quality (a sense of having received genuine knowledge), and a quality of sacredness that he distinguished from ordinary religious feeling.

In 2006, Roland Griffiths and colleagues at Johns Hopkins published the first rigorous modern trial of psilocybin's ability to occasion mystical experience. They used the Mystical Experience Questionnaire (MEQ30), derived from the philosopher Walter Stace's phenomenological analysis of mystical states. The MEQ30 measures six features: unity, noetic quality, sacredness, deeply felt positive mood, transcendence of time and space, and ineffability.

These are Huxley's criteria, operationalized. Not quite in his language, Stace and Griffiths use the vocabulary of phenomenology and psychology rather than Vedantic philosophy, but the underlying structure is identical. The MEQ30 is measuring what Huxley described as the 'gratuitous grace': the direct encounter with what the reducing valve ordinarily prevents.

The Griffiths 2006 trial found that psilocybin could reliably occasion complete mystical experiences (MEQ30 score above 60 percent of maximum) in a significant proportion of participants in appropriate conditions. At fourteen-month follow-up, the majority of those who had complete mystical experiences rated them among the most meaningful of their lives. The finding has been replicated multiple times since.

What has been more significant for clinical practice is the subsequent finding that mystical experience quality predicts therapeutic outcomes better than drug dose alone. In studies of psilocybin for depression, end-of-life anxiety, and alcohol use disorder, MEQ30 scores correlate with treatment response at follow-up. Participants who have complete mystical experiences are more likely to show sustained therapeutic benefit than those who have sub-threshold experiences, even when the dose is the same.

This finding has profound implications. It suggests that the therapeutic mechanism of psychedelic-assisted therapy is not simply pharmacological, not just the drug acting on receptors to produce symptomatic relief. It suggests that the quality of the experience, whether it reaches the threshold of genuine transformation, is what drives the outcome. The medicine is not the molecule but what the molecule occasions.

Huxley articulated this distinction in 1954: the drug is a vehicle, not a destination. What it delivers is not itself the healing; what it delivers is a quality of experience that the person must then bring into their life. The letters to Osmond contain his worry that people who focused on the drug rather than the experience it opened would miss the point entirely.

The two industry Phase 3 trials of synthetic psilocybin, reporting in June 2025 and February 2026 respectively, showed statistically significant reductions in MADRS (Montgomery-Åsberg Depression Rating Scale) scores in treatment-resistant depression patients who received a single high dose of synthetic psilocybin alongside psychotherapeutic support. Twenty-five percent of participants achieved clinically meaningful reduction at six weeks, with durability through twenty-six weeks. The NDA submission is targeted for Q4 2026.

These are modest numbers by the standards of antidepressant trials, but the comparison is inexact. Standard antidepressants require daily dosing indefinitely; synthetic psilocybin is one or two doses. Standard antidepressants produce response rates that cluster around 40-50 percent in treatment-naive patients and fall sharply in treatment-resistant patients; synthetic psilocybin is being tested in patients who have already failed at least two antidepressants.

What the trials are measuring, beneath the MADRS scores and the Phase 3 endpoints, is what Huxley proposed in 1954: that direct perceptual encounter with something beyond the ordinary reducing valve's output can produce lasting change in how a person relates to their experience. The clinical infrastructure for testing this claim did not exist in 1954. It now does, and what it is finding is that the claim was substantially correct.

The EPISODE trial, published in JAMA Psychiatry in May 2026, found that high-dose psilocybin produced treatment response (defined as ≥50% reduction in Hamilton Depression Rating Scale) in significantly more participants than active placebo at six weeks, in a German multicenter Phase 2b trial. The effect sizes are clinically meaningful and the safety profile is well-characterized. Huxley's 'gratuitous grace' is being measured in clinical endpoints. The measurement doesn't reduce what it measures.

Sources

• Huxley, The Doors of Perception (1954)
• Griffiths et al., Psilocybin can occasion mystical-type experiences, Psychopharmacology (2006)
• Yaden et al., The Varieties of Self-Transcendent Experience, Review of General Psychology (2017)
• Barrett & Griffiths, Classic Hallucinogens and Mystical Experiences, Curr Top Behav Neurosci (2018)
• Industry Phase 3 psilocybin trial results (2025-2026)